NasdaqGS:AMPH

Stock Analysis Report

Executive Summary

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France.

Snowflake

Fundamentals

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Amphastar Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.5%

NasdaqGS:AMPH

1.9%

US Pharmaceuticals

2.1%

US Market


1 Year Return

25.2%

NasdaqGS:AMPH

-6.0%

US Pharmaceuticals

-0.04%

US Market

AMPH outperformed the Pharmaceuticals industry which returned -5.8% over the past year.

AMPH outperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

AMPHIndustryMarket
7 Day5.5%1.9%2.1%
30 Day15.3%-1.7%-3.2%
90 Day6.4%-3.5%2.8%
1 Year25.2%25.2%-3.7%-6.0%2.2%-0.04%
3 Year16.0%16.0%11.3%3.7%41.5%32.3%
5 Year86.6%86.6%23.4%10.4%55.0%37.8%

Price Volatility Vs. Market

How volatile is Amphastar Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amphastar Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Amphastar Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Amphastar Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Amphastar Pharmaceuticals is overvalued based on earnings compared to the US Pharmaceuticals industry average.

Amphastar Pharmaceuticals is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Amphastar Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Amphastar Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Amphastar Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

14.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Amphastar Pharmaceuticals's revenue is expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).

Amphastar Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Amphastar Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Amphastar Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Amphastar Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Amphastar Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Amphastar Pharmaceuticals performed over the past 5 years?

40.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Amphastar Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.

Amphastar Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Amphastar Pharmaceuticals has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.


Return on Equity

Amphastar Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Amphastar Pharmaceuticals used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Amphastar Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Amphastar Pharmaceuticals's financial position?


Financial Position Analysis

Amphastar Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Amphastar Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Amphastar Pharmaceuticals's level of debt (10.8%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (18.6% vs 10.8% today).

Debt is well covered by operating cash flow (157.1%, greater than 20% of total debt).

Amphastar Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 6.1x debt.


Next Steps

Dividend

What is Amphastar Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Amphastar Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Amphastar Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Amphastar Pharmaceuticals has not reported any payouts.

Unable to verify if Amphastar Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Amphastar Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Amphastar Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

10.4yrs

Average management tenure


CEO

Jack Zhang (72yo)

23.6yrs

Tenure

US$5,874,707

Compensation

Dr. Yongfeng Zhang, also known as Jack, Ph.D., co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive Officer and Chief Science Officer since 1996 and 2005 respectively and served as ...


CEO Compensation Analysis

Jack's remuneration is higher than average for companies of similar size in United States of America.

Jack's compensation has increased in line with Amphastar Pharmaceuticals recently becoming profitable.


Management Age and Tenure

10.4yrs

Average Tenure

60yo

Average Age

The average tenure for the Amphastar Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

16.0yrs

Average Tenure

70.5yo

Average Age

The average tenure for the Amphastar Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

Amphastar Pharmaceuticals individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$103,78216 Aug 19
William Peters
EntityIndividual
Role
Chief Financial Officer
CFO, Treasurer & Senior VP of Finance
Shares4,942
Max PriceUS$21.00
SellUS$33,37018 Dec 18
Richard Prins
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,616
Max PriceUS$20.65
SellUS$892,30918 Dec 18
Yongfeng Zhang
EntityIndividual
Role
Chief Executive Officer
CEO, Chief Science Officer & Director
Shares43,577
Max PriceUS$20.48
SellUS$2,851,05214 Dec 18
Applied Physics & Chemistry Laboratories, Inc.
EntityCompany
Shares133,915
Max PriceUS$22.13
SellUS$53,26904 Dec 18
Jacob Liawatidewi
EntityIndividual
Role
Head of Sales
Senior VP of Corporate Administration Center
Shares2,480
Max PriceUS$21.48
SellUS$31,14029 Nov 18
Jacob Liawatidewi
EntityIndividual
Role
Head of Sales
Senior VP of Corporate Administration Center
Shares1,520
Max PriceUS$20.49
SellUS$26,31527 Nov 18
Jacob Liawatidewi
EntityIndividual
Role
Head of Sales
Senior VP of Corporate Administration Center
Shares1,299
Max PriceUS$20.26

Ownership Breakdown


Management Team

  • Bill Peters (51yo)

    CFO, Treasurer & Senior VP of Finance

    • Tenure: 5.3yrs
  • Jack Zhang (72yo)

    CEO, Chief Science Officer & Director

    • Tenure: 23.6yrs
    • Compensation: US$5.87m
  • Mary Luo (69yo)

    Chairman of the Board

    • Tenure: 23.6yrs
    • Compensation: US$3.03m
  • Peter Langosh (66yo)

    Vice President of Operational Improvement and Vice President of Internal Audit

    • Tenure: 18.6yrs
    • Compensation: US$162.64k
  • Eva Wen

    Director of System Control

    • Tenure: 14.6yrs
  • Jason Shandell (45yo)

    President

    • Tenure: 9.6yrs
    • Compensation: US$2.58m
  • Rong Zhou (60yo)

    Executive VP of Production & President of Armstrong

    • Tenure: 4.2yrs
  • Jacob Liawatidewi (45yo)

    Senior VP of Corporate Administration Center

    • Tenure: 5.7yrs

Board Members

  • Michael Zasloff (73yo)

    Lead Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$300.00k
  • Richard Prins (62yo)

    Independent Director

    • Tenure: 17.5yrs
    • Compensation: US$293.00k
  • Howard Lee (58yo)

    Independent Director

    • Tenure: 12.0yrs
    • Compensation: US$299.50k
  • Jack Zhang (72yo)

    CEO, Chief Science Officer & Director

    • Tenure: 23.6yrs
    • Compensation: US$5.87m
  • Chen Yang

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Paul White

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Gordon Treweek (76yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Mary Luo (69yo)

    Chairman of the Board

    • Tenure: 23.6yrs
    • Compensation: US$3.03m
  • Richard Koo (78yo)

    Independent Director

    • Tenure: 16.0yrs
    • Compensation: US$300.00k
  • Jason Shandell (45yo)

    President

    • Tenure: 9.6yrs
    • Compensation: US$2.58m

Company Information

Amphastar Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amphastar Pharmaceuticals, Inc.
  • Ticker: AMPH
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.065b
  • Shares outstanding: 47.23m
  • Website: https://www.amphastar.com

Number of Employees


Location

  • Amphastar Pharmaceuticals, Inc.
  • 11570 6th Street
  • Rancho Cucamonga
  • California
  • 91730
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMPHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2014
29ADB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 00:13
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.